A regulatory panel recommended Wednesday that approval of Genentech Inc.’s cancer-fighting drug Avastin be revoked for women with breast cancer that has spread to other parts of the body.
The Food and Drug Administration panel in a 6-0 vote said two followup clinical trials did not verify the clinical effect of Avastin for women with metastatic breast cancer.
The final say rests with FDA Commissioner Margaret Hamburg, likely later this summer. The decision could shave about $1 billion in revenue off of Avastin, the world’s best-selling cancer drug.
No comments:
Post a Comment